The research-based pharmaceutical industry says the decision to waive intellectual property protections for COVID-19 vaccines is fundamentally flawed and will have a negative impact on future innovation.
Research-based industry says IP waiver an 'empty shell' and fact-free decision
June 19, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Health spending under increasing pressure, as department looks to offsets
July 9, 2025 - - Latest News -
AusBiotech welcomes 27 new members in first half of 2025
July 9, 2025 - - Latest News -
Consortium established to co-design new telehealth standards
July 8, 2025 - - Latest News -
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech